Myriad Genetics (MYGN) Misses Q4 EPS by 1c; Guides Below the Street
Get Alerts MYGN Hot Sheet
Financial Fact:
Research and development expense: 19.4M
Today's EPS Names:
BVFL, MCET, REOS, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.41, $0.01 worse than the analyst estimate of $0.42. Revenue for the quarter came in at $189.9 million versus the consensus estimate of $187.77 million.
Myriad Genetics sees FY2016 EPS of $1.60-$1.65, versus the consensus of $1.75. Myriad Genetics sees FY2016 revenue of $750-770 million, versus the consensus of $760.07 million.
Myriad Genetics sees Q1 2016 EPS of $0.34-$0.36, versus the consensus of $0.40. Myriad Genetics sees Q1 2016 revenue of $176-178 million, versus the consensus of $185.1 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Globe Life Inc. (GL) Misses Q1 EPS by 1c, Offers Guidance
- Medpace Holdings (MEDP) Tops Q1 EPS by 72c ; Offers Guidance
- SAP SE (SAP) Misses Q1 EPS by 25c; offers outlook
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!